Related Experiment Video
Updated: Sep 23, 2025
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Identification of significant genes with a poor prognosis in skin cutaneous malignant melanoma based on a
Jin Wang1,2,3,4, Jilong Yang1,2
1Department of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Background:
Skin cutaneous malignant melanoma (SKCM) is a deadly mutated malignancy that arises from melanocytes in the basal layer of the skin. This study sought to identify effective treatment targets that could serve as prospective therapeutic targets to improve patient outcomes.
Methods:
The GSE83583, GSE111766, and GSE104849 data sets from the GPL10558 platform in the Gene Expression Omnibus (GEO) were used in this study. The candidate genes were identified using the GEO2R tool and a Venn diagram. The Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Gene and Genome (KEGG) preliminary analyses of the differentially expressed genes (DEGs) were conducted using the Database for Annotation, Visualization and Integrated Discovery, and R software. The protein-protein interaction (PPI) network was examined using Cytoscape software. The survminer package was used to examine the overall survival of patients with the identified genes. The Human Protein Atlas (HPA) was used to verify the protein levels of significant genes with poor prognosis. The highly expressed genes in the melanoma tissues were visualized using the ggplot2 package.
Results:
In total, 160 DEGs from 124 melanoma tissues and 9 normal melanocyte tissues were examined in this study. Cytoscape displayed 19 central nodes from the 160 DEGs. The re-analysis showed that the cytochrome P450 family 1 subfamily B member 1 (CYP1B1) and protein kinase C beta (PRKCB) were significantly enriched in the micro ribonucleic acids (RNAs) in cancer.
Conclusions:
CYP1B1 and PRKCB were overexpressed in and correlated with the poor prognosis of SKCM. Our findings might help explore the prognosis and diagnostic markers of SKCM.
Insights
This study identified two key genes, CYP1B1 and PRKCB, as potential therapeutic targets for skin cutaneous malignant melanoma (SKCM). These genes are overexpressed in melanoma and linked to poor patient prognosis, offering new avenues for diagnosis and treatment.
Area of Science:
- Oncology
- Genetics
- Bioinformatics
Background:
- Skin cutaneous malignant melanoma (SKCM) is a significant cancer arising from melanocytes.
- Identifying effective therapeutic targets is crucial for improving SKCM patient outcomes.
Purpose of the Study:
- To identify novel therapeutic targets for skin cutaneous malignant melanoma (SKCM).
- To explore potential prognostic and diagnostic markers for SKCM.
Main Methods:
- Utilized Gene Expression Omnibus (GEO) datasets (GSE83583, GSE111766, GSE104849) and GEO2R for differential gene expression analysis.
- Performed Gene Ontology (GO) and Kyoto Encyclopedia of Gene and Genome (KEGG) enrichment analyses, constructed protein-protein interaction (PPI) networks using Cytoscape.
- Analyzed overall survival using survminer and validated protein levels with the Human Protein Atlas (HPA).
Main Results:
- Identified 160 differentially expressed genes (DEGs) between melanoma and normal tissues.
- Discovered cytochrome P450 family 1 subfamily B member 1 (CYP1B1) and protein kinase C beta (PRKCB) as significantly enriched genes.
- Found CYP1B1 and PRKCB to be overexpressed in melanoma and correlated with poor prognosis.
Conclusions:
- CYP1B1 and PRKCB are overexpressed in SKCM and associated with unfavorable patient prognosis.
- These genes represent promising candidates for prognostic and diagnostic markers in SKCM.
- The findings support further investigation of CYP1B1 and PRKCB as therapeutic targets for SKCM.
